Table 1

Patients’ characteristics

PatientAgeBMIaTNM% ERb% PgRbMet.Resp.c-erbB-2cEGF-Rc
15628.0T3N0M02.0d0.0PDpos./pos.pos./pos.
27322.4T4N2M198.00.0boneMCneg./neg.neg./neg.
36730.8T4N2M186.053.0bonePRneg./neg.neg./neg.
46731.9T3N1M092.086.0MCneg./neg.neg./neg.
55530.5T3N2M087.070.0MCneg./neg.neg./neg.
67029.9T2N2M082.07.5PDneg./neg.neg./neg.
75826.4T3N0M00.0d4.3StDpos./pos.neg./neg.
87029.2T4N0M193.00.0skinPRneg./neg.neg./neg.
96625.8T3N1M092.079.0StDneg./neg.neg./neg.
108026.9T3N1M091.086.0StDneg./neg.neg./neg.
116025.4T4N1M0n.a.dn.a.StDn.a./neg.n.a./neg.
126522.0T4N0M083.084.0PRneg./neg.neg./neg.
  • a BMI, body mass index; TNM, tumor-node-metastasis; Met., metastasis; Resp., response; PD, progressive disease; pos., positive; MC, minimal change; neg., negative; PR, partial response; StD, stable disease; n.a., not available.

  • b Expressed as percentage of cells staining positively (IHC).

  • c Staining for c-erbB-2 and EGF-R is given prior to treatment with anastrozole (x/) and after 15 weeks (median) on treatment (/x).

  • d ER levels ≥ 10 fmol/mg were confirmed by the charcoal method prior to treatment with anastrozole.